Accepted for Publication: March 15, 2011.
Published Online: June 20, 2011. doi:10.1001/archfacial.2011.37
Author Contributions: Dr Maas, the principal investigator, and Dr Nettar had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Nettar, Bapna, and Maas. Acquisition of data: Nettar, Yu, and Maas. Analysis and interpretation of data: Nettar, Yu, Boscardin, and Maas. Drafting of the manuscript: Nettar, Yu, Bapna, and Maas. Critical revision of the manuscript for important intellectual content: Nettar, Boscardin, and Maas. Statistical analysis: Nettar, Boscardin, and Maas. Obtained funding: Bapna and Maas. Administrative, technical, and material support: Nettar, Yu, and Maas. Study supervision: Maas.
Financial Disclosure: Dr Maas is a consultant and owns stock in both Medicis Aesthetics Inc (makers of abobotulinumtoxinA) and Allergan Inc (makers of onabotulinumtoxinA).
Funding/Support: Funding for this study was solicited from both Medicis Aesthetics Inc and Allergan Inc. Medicis Aesthetics Inc funded this study.
Previous Presentation: This study was presented in part at the Fall Meeting of the American Academy of Facial Plastic and Reconstructive Surgery; September 24, 2010; Boston, Massachusetts.